These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 3887213)

  • 1. Long-term experience with pergolide therapy of advanced parkinsonism.
    Kurlan R; Miller C; Levy R; Macik B; Hamill R; Shoulson I
    Neurology; 1985 May; 35(5):738-42. PubMed ID: 3887213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy of pergolide in patients with Parkinson's disease.
    Sage JI; Duvoisin RC
    Clin Neuropharmacol; 1986; 9(2):160-4. PubMed ID: 3708601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical study of pergolide in Parkinson's disease].
    Gonce M; Delwaide PJ
    Presse Med; 1985 Jun; 14(26):1409-11. PubMed ID: 3161045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of pergolide and mesulergine.
    Lieberman AN; Gopinathan G; Neophytides A
    Eur Neurol; 1986; 25(2):86-90. PubMed ID: 3948891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide.
    Goetz CG; Tanner CM; Glantz RH; Klawans HL
    Neurology; 1985 May; 35(5):749-51. PubMed ID: 3990974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled trial of pergolide mesylate in Parkinson's disease and progressive supranuclear palsy.
    Jankovic J
    Neurology; 1983 Apr; 33(4):505-7. PubMed ID: 6339985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of pergolide, a potent dopamine agonist, in Parkinson's disease.
    Lieberman AN; Goldstein M; Neophytides A; Leibowitz M; Gopinathan G; Walker R; Pact V
    Clin Pharmacol Ther; 1982 Jul; 32(1):70-5. PubMed ID: 7083733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pergolide and lisuride in advanced Parkinson's disease.
    Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Goldstein M
    Adv Neurol; 1984; 40():503-7. PubMed ID: 6695627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesulergine and pergolide in previously untreated Parkinson's disease.
    Wright A; Lees AJ; Stern GM
    J Neurol Neurosurg Psychiatry; 1987 Apr; 50(4):482-4. PubMed ID: 3585362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of REM rebound by Pergolide.
    Askenasy JJ; Yahr MD
    J Neural Transm; 1984; 59(2):151-9. PubMed ID: 6726217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of pergolide and lisuride, two experimental dopamine agonists, in patients with advanced Parkinson disease.
    Lieberman AN; Leibowitz M; Gopinathan G; Walker R; Hiesiger E; Nelson J; Goldstein M
    Am J Med Sci; 1985 Sep; 290(3):102-6. PubMed ID: 4050844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Further studies with pergolide in Parkinson disease.
    Lieberman AN; Goldstein M; Gopinathan G; Leibowitz M; Neophytides A; Walker R; Hiesiger E; Nelson J
    Neurology; 1982 Oct; 32(10):1181-4. PubMed ID: 6889703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pergolide mesylate: lack of cardiac toxicity in patients with cardiac disease.
    Tanner CM; Chhablani R; Goetz CG; Klawans HL
    Neurology; 1985 Jun; 35(6):918-21. PubMed ID: 3889707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of advanced Parkinson disease with pergolide.
    Lieberman A; Goldstein M; Leibowitz M; Neophytides A; Kupersmith M; Pact V; Kleinberg D
    Neurology; 1981 Jun; 31(6):675-82. PubMed ID: 7195484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Painful dystonic spasms in Parkinson's disease.
    Ilson J; Fahn S; Côté L
    Adv Neurol; 1984; 40():395-8. PubMed ID: 6695618
    [No Abstract]   [Full Text] [Related]  

  • 16. Pergolide in the treatment of Parkinson's disease.
    Quinn NP; Lang AE; Thompson C; Brincat S; Marsden CD; Parkes JD
    Adv Neurol; 1984; 40():509-13. PubMed ID: 6695628
    [No Abstract]   [Full Text] [Related]  

  • 17. A 6-month trial of pergolide mesylate in the treatment of idiopathic Parkinson's disease.
    Klawans HL; Tanner CM; Glatt S; Goetz CG
    Adv Neurol; 1983; 37():75-83. PubMed ID: 6344592
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term treatment with pergolide: decreased efficacy with time.
    Lieberman AN; Goldstein M; Leibowitz M; Gopinathan G; Neophytides A; Hiesiger E; Nelson J; Walker R
    Neurology; 1984 Feb; 34(2):223-6. PubMed ID: 6538014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term study of pergolide in Parkinson's disease.
    Jankovic J
    Neurology; 1985 Mar; 35(3):296-9. PubMed ID: 3974887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.